HC Wainwright Issues Pessimistic Forecast for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Research analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for Eton Pharmaceuticals in a research report issued on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $0.00 per share for the quarter, down from their prior estimate of $0.08. HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.13 EPS and Q4 2025 earnings at $0.19 EPS.

Other research analysts have also issued research reports about the company. B. Riley reissued a “buy” rating and issued a $24.00 target price (up previously from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday.

Eton Pharmaceuticals Stock Up 15.1%

Shares of ETON stock opened at $19.70 on Friday. The stock’s 50-day moving average price is $14.72 and its 200 day moving average price is $13.82. The stock has a market capitalization of $528.31 million, a PE ratio of -89.55 and a beta of 1.22. Eton Pharmaceuticals has a 52-week low of $3.18 and a 52-week high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The business had revenue of $17.28 million for the quarter, compared to analysts’ expectations of $14.33 million.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of large investors have recently modified their holdings of the business. PDT Partners LLC acquired a new position in Eton Pharmaceuticals during the first quarter worth $334,000. Nantahala Capital Management LLC grew its stake in shares of Eton Pharmaceuticals by 5.1% during the 1st quarter. Nantahala Capital Management LLC now owns 1,175,951 shares of the company’s stock worth $15,264,000 after purchasing an additional 57,468 shares during the period. Cubist Systematic Strategies LLC increased its holdings in shares of Eton Pharmaceuticals by 138.7% in the 1st quarter. Cubist Systematic Strategies LLC now owns 103,200 shares of the company’s stock valued at $1,340,000 after purchasing an additional 59,961 shares in the last quarter. State of Wyoming purchased a new stake in Eton Pharmaceuticals during the first quarter worth about $343,000. Finally, AlphaQuest LLC purchased a new stake in Eton Pharmaceuticals during the first quarter worth about $53,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.